LCN2 and colorectal cancer: While NGAL does not interfere with doxorubicin resistance in breast and colorectal cancer cells [73], it might favor the intracellular accumulation of other chemotherapeutic drugs in breast cancer [28], renal cancer [71], glioblastoma [70], oral squamous cancer [46] and leukemic AML [43] cell lines.